Circio terminates TG01 cancer vaccine license option agreement with IOVaxis in China for non-payment
Oslo, Norway 17 April 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy and cancer vaccines, announces that it has terminated the exclusive TG01 KRAS cancer vaccine license option agreement with IOVaxis therapeutics in Greater China and Singapore On 1 March 2024, IOVaxis Therapeutics´ IND-application to initiate TG01 clinical development in China was approved, triggering a USD 3 million license fee to Circio. Circio initially granted IOVaxis a six-month payment extension following an immediate USD 300,